Synthase Biotech is a start-up company commercialising a novel enzyme technology that works to prevent and repair damage caused by the oxidation of lipids in cell membranes, a key process for damage and aging within cells.
The Aloxsyn® enzyme has the potential to significantly extend the lifespan of cellular products. Currently, Aloxsyn® is being applied in the fertility space to improve artificial insemination (AI) and IVF practices and outcomes in livestock as a beachhead market. This enzyme has broad potential applications, from improving shelf life of foods to treating a wide range of damaging medical conditions in humans. Matū works closely with Synthase to provide strong governance, capital raising expertise, and support their ongoing strategy and business development.